No Data
Hutchmed/Innovent Update on Phase 2/3 Study of Fruquintinib+Sintilimab
HUTCHMED and Innovent's Combination Therapy Shows Promise in Advanced Renal Cell Carcinoma
INNOVENT BIO and Hutchmed (China) announced that the FRUSICA-2 China Phase II/III study of sintilimab in combination with fruquintinib for the treatment of advanced renal cell carcinoma has met its primary endpoint.
INNOVENT BIO Pharmaceutical Group (HKEX stock code: 01801) is a biopharmaceutical company dedicated to the research, production, and sales of Innovative Drugs in major disease areas such as oncology, autoimmune diseases, metabolism, and ophthalmology. Today, it announced in collaboration with Hutchmed (China) Limited ("Hutchmed", Nasdaq/London Stock Exchange: HCM; HKEX: 13) that the FRUSICA-2 China Phase II/III study of the combination therapy of Sintilimab and Furmonertinib for second-line treatment of locally advanced or metastatic renal cell carcinoma has reached the primary endpoint of progression-free survival (PFS) as assessed by blinded independent central review (BICR) according to RECIST 1.1 criteria.
Hutchmed (China) (00013.HK) and INNOVENT BIO announced that the FRUSICA-2 Phase II/III study in China of fruquintinib combined with sintilimab for the treatment of advanced renal cell carcinoma has reached its primary endpoint.
On March 19, Gelonghui reported that Hutchmed (China) (00013.HK) and INNOVENT BIO announced today that the combination therapy of fruquintinib and sintilimab for second-line treatment of locoregional advanced or metastatic renal cell carcinoma has achieved the primary endpoint of progression-free survival ("PFS") assessed by blinded independent central review (BICR) according to RECIST 1.1 standards in the FRUSICA-2 China Phase II/III study. The combination therapy of fruquintinib and sintilimab was earlier based on the FRUSICA-1 study.
Express News | HUTCHMED and Innovent Jointly Announce That the Frusica-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China
Trending Industry Today: BIDU-SW Leads Gains In HKEX Secondary Listings Stocks
